LFCR vs. ACRV, TRVI, GALT, RIGL, OMER, GBIO, OVID, ATOS, RENB, and ALIM
Should you be buying Lifecore Biomedical stock or one of its competitors? The main competitors of Lifecore Biomedical include Acrivon Therapeutics (ACRV), Trevi Therapeutics (TRVI), Galectin Therapeutics (GALT), Rigel Pharmaceuticals (RIGL), Omeros (OMER), Generation Bio (GBIO), Ovid Therapeutics (OVID), Atossa Therapeutics (ATOS), Renovaro (RENB), and Alimera Sciences (ALIM). These companies are all part of the "pharmaceutical preparations" industry.
Acrivon Therapeutics (NASDAQ:ACRV) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.
Acrivon Therapeutics has higher earnings, but lower revenue than Lifecore Biomedical. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.
Acrivon Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.
71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 7.3% of Acrivon Therapeutics shares are held by company insiders. Comparatively, 14.6% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Acrivon Therapeutics' return on equity of 0.00% beat Lifecore Biomedical's return on equity.
Acrivon Therapeutics currently has a consensus target price of $22.88, indicating a potential upside of 157.31%. Lifecore Biomedical has a consensus target price of $9.50, indicating a potential upside of 61.84%. Given Lifecore Biomedical's stronger consensus rating and higher probable upside, equities analysts clearly believe Acrivon Therapeutics is more favorable than Lifecore Biomedical.
In the previous week, Acrivon Therapeutics had 11 more articles in the media than Lifecore Biomedical. MarketBeat recorded 16 mentions for Acrivon Therapeutics and 5 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.71 beat Acrivon Therapeutics' score of 0.13 indicating that Acrivon Therapeutics is being referred to more favorably in the media.
Acrivon Therapeutics received 24 more outperform votes than Lifecore Biomedical when rated by MarketBeat users. Likewise, 96.15% of users gave Acrivon Therapeutics an outperform vote while only 12.50% of users gave Lifecore Biomedical an outperform vote.
Summary
Acrivon Therapeutics beats Lifecore Biomedical on 10 of the 16 factors compared between the two stocks.
Get Lifecore Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for LFCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LFCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lifecore Biomedical Competitors List
Related Companies and Tools
